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Abstract
The splicing factor SF3B1 is the most frequently mutated gene in the myelodysplastic syndromes 
(MDS), and is strongly associated with the presence of ring sideroblasts (RS). We have performed 
a systematic analysis of cryptic splicing abnormalities from RNA-sequencing data on 
hematopoietic stem cells (HSCs) of SF3B1-mutant MDS cases with RS. Aberrant splicing events 
in many downstream target genes were identified and cryptic 3’ splice site usage was a frequent 
event in SF3B1-mutant MDS. The iron transporter ABCB7 is a well-recognized candidate gene 
showing marked downregulation in MDS with RS. Our analysis unveiled aberrant ABCB7 
splicing, due to usage of an alternative 3’ splice site in MDS patient samples, giving rise to a 
premature termination codon in the ABCB7 mRNA. Treatment of cultured SF3B1-mutant MDS 
erythroblasts and a CRISPR/Cas9-generated SF3B1-mutant cell line with the nonsense-mediated 
decay (NMD) inhibitor cycloheximide, showed that the aberrantly spliced ABCB7 transcript is 
targeted by NMD. We describe cryptic splicing events in the HSCs of SF3B1-mutant MDS, and 
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our data support a model in which NMD-induced downregulation of the iron exporter ABCB7 
mRNA transcript resulting from aberrant splicing caused by mutant SF3B1 underlies the increased 
mitochondrial iron accumulation found in MDS patients with RS.
Keywords
myelodysplastic syndromes; SF3B1; splicing; ABCB7; RARS
Introduction
The myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic 
stem cell (HSC) malignancies characterized by ineffective hematopoiesis leading to 
peripheral blood cytopenias, and show increasing bone marrow blasts.1 The MDS show 
frequent progression (approximately 40% of patients) to acute myeloid leukemia (AML). 
Several genes involved in pre-mRNA splicing, including SF3B1, U2AF1, SRSF2 and 
ZRSR2,2–4 have been shown to be mutated in over 50% of MDS patients, revealing a new 
leukemogenic pathway involving spliceosomal dysfunction.
The splicing factor SF3B1 is the most frequently mutated gene in patients with MDS (20–
28% of all cases).5,6 Mutations of SF3B1 occur in a high proportion (>80%) of MDS 
patients in which the presence of ring sideroblasts is a characteristic disease feature, namely 
the refractory anemia with ring sideroblasts (RARS) and refractory cytopenia with 
multilineage dysplasia and ring sideroblasts (RCMD-RS) subtypes.5,7 In the recent 2016 
revision of the World Health Organization (WHO) classification for MDS, if a patient 
harbors an SF3B1 mutation, a diagnosis of MDS with ring sideroblasts (MDS-RS) may be 
made if 5-14% ring sideroblasts are present in the bone marrow.8 SF3B1 mutations are 
closely associated with the presence of ring sideroblasts, suggesting a causal relationship 
and making SF3B1 the first gene showing a strong association with a particular 
morphological feature in MDS.5 Ring sideroblasts are erythroblasts with excessive 
mitochondrial iron accumulation,9 and RARS patients with SF3B1 mutation have altered 
iron distribution characterized by coarse iron deposits in comparison to RARS patients 
without SF3B1 mutation.10 SF3B1 mutations occur more frequently in low-risk MDS cases 
and are independent predictors of favorable survival in MDS.5 The clinical consequences of 
mutations in SF3B1 are well documented in MDS, however the functional consequences of 
SF3B1 mutations in human hematopoietic cells are not fully understood.
A well-recognized candidate gene for MDS with the ring sideroblast phenotype is the iron 
transporter ABCB7. Our group first reported marked downregulation of ABCB7 in MDS 
patients with RARS subtype.11 Hereditary X-linked sideroblastic anemia with ataxia is 
caused by partial loss of function mutations of ABCB7, which inhibit heme biosynthesis.12 
Moreover, knockdown of ABCB7 in HeLa cells resulted in an iron-deficient phenotype with 
mitochondrial iron accumulation.13 Conditional gene targeting in mice has shown that 
ABCB7 is essential for hematopoiesis.12
SF3B1 is a core component of the U2-small nuclear ribonucleoprotein (U2-snRNP) complex 
and is involved in stabilizing the interaction of the U2-snRNP with the branch point (BP),14 
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upstream of the 3’ splice site. SF3B1 also interacts with other spliceosomal proteins such as 
U2AF2, which binds the polypyrimidine tract (PPT) downstream of the BP.15,16 Base-
pairing of U2 snRNA with the pre-mRNA bulges out the BP adenosine, specifying it as the 
site to initiate the nucleophilic attack in the first step of splicing. The binding of the SF3B 
complex proteins around the BP prevents the premature activity at the site before the fully 
active spliceosome is assembled.17 The role of SF3B1 and the U2-snRNP in recognizing 
and binding the BP suggest that SF3B1 mutations may alter BP and/or 3’ splice site 
selection.
The splicing factor genes found to be mutated in MDS code for proteins that play a role in 
the recognition of 3’ splice sites during processing of pre-messenger RNAs (pre-mRNAs).3 
Altered RNA splicing has been suggested as the mechanism underlying the observed 
phenotypic changes concomitant to splicing factor gene mutations, including SF3B1, and the 
identification of aberrantly spliced target genes in the hematopoietic cells of SF3B1 mutant 
MDS cases is important.
A number of studies to date have used RNA sequencing (RNA-Seq) on unfractionated bone 
marrow mononuclear cells from a small number of SF3B1-mutant MDS patients.10,18,19 
MDS is a disorder of the HSC and we thus studied the transcriptome of CD34+ cells from 
MDS patients with SF3B1 mutations using RNA-Seq. We have recently identified many 
genes significantly differentially expressed at the transcript and/or exon level in bone 
marrow CD34+ cells of SF3B1-mutant MDS compared with wildtype and healthy control 
cases.20
Recently, SF3B1 mutations have been identified in various tumor types, suggesting that 
somatic mutations in spliceosome genes play an important role in tumorigenesis.21–24 
SF3B1 mutations have been shown to occur in chronic lymphocytic leukemia (CLL), uveal 
melanoma (UM), breast cancer (BRCA) and pancreatic cancer.24,25 SF3B1 mutations have 
clear mutational hotspots and are considered to be gain-of-function/neomorphic mutations.
2,3,26,27 The codons most commonly affected by SF3B1 mutations in other cancers that 
harbor this mutation, including  chronic lymphocytic leukemia (CLL), uveal melanoma 
(UM), breast cancer (BRCA) and pancreatic cancer, are the same as the ones affected in 
MDS (K700E, R625 and K666). Recent studies of CLL, BRCA and UM using RNA-Seq 
have shown that SF3B1 mutations are associated with differential exon usage and induce 
cryptic alternative 3’ splice site selection in these cancers.28 However, a systematic analysis 
of cryptic splicing abnormalities has not been performed in MDS HSCs.
In this study, we have performed an analysis of RNA-Seq data on HSCs of SF3B1-mutant 
MDS cases in order to identify aberrant/cryptic splicing events. The identification of the 
splicing aberrations induced by SF3B1 mutation in the HSCs of MDS patients will shed 
light on the downstream effects that lead to the MDS phenotype and may allow for the 
identification of new therapeutic targets in this disease.
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Materials and Methods
Samples and RNA-Seq
RNA-Seq data were obtained from CD34+ cells isolated from bone marrow samples of eight 
MDS patients (four RARS and four RCMD-RS) with SF3B1 mutation (four K700E, one 
E622D, one R625L, one H662Q and one K666R; 45-52% SF3B1 mutant allele expression 
range), four MDS cases (all RCMD) without mutations in the splicing factor genes SF3B1, 
SRSF2, U2AF1 and ZRSR2, and five healthy individuals.20 CD34+ cells were isolated from 
bone marrow samples of the 12 MDS patients and five healthy controls using MACS 
columns (Miltenyi Biotec, Germany), according the to manufacturer’s recommendations.
DNase-treated (Invitrogen) total RNA was purified using XP beads (Beckman Coulter, UK), 
and library preparation was performed using the NEBNext Ultra directional RNA Library 
prep kit (NEB, UK) following the manufacturer’s recommendations. Custom indexes were 
used and samples were purified using XP beads (Beckman Coulter) instead of size selection. 
Sequencing was performed on an Illumina HiSeq2000 instrument (Illumina, USA).
RNA-Seq data analysis
Following QC analysis with the fastQC package (http://
www.bioinformatics.babraham.ac.uk/projects/fastqc), reads were aligned using STAR29 
against the human genome assembly [NCBI build37 (hg19) UCSC transcripts]. Non-
uniquely mapped reads and reads that were identified as PCR duplicates using Samtools30 
were discarded. The aligned reads were reconstructed into transcripts using Cufflinks31 and 
were then merged into a single assembly, along with known isoforms from the NCBI 
build37 (hg19) UCSC transcripts. This reference-guided assembly was then used as the 
transcripts annotation by rMATS.
Alternative 3′ and 5′ splice sites, skipped exons, mutually exclusive exons, and retained 
introns were quantified using rMATS32 with the assembly produced from Cufflinks. The 
default parameters were used for the comparison of the samples. The results were filtered 
using a false-discovery rate <0.05 and inclusion level difference values >0.3 or <-0.3. The 
alternative spliced events were then plotted using the sashimi plots of the MISO software.33 
The results were visualized and filtered using the data visualization tool Zegami (http://
zegami.com/).
Gene Ontology analysis
See Supplementary Methods.
Analysis of 3’ splice site properties
See Supplementary Methods.
End point RT-PCR validation of aberrant splicing isoforms
Six genes (including ABCB7) with cryptic 3’ splice sites were selected from the rMATS 
data analysis for end point reverse transcriptase-PCR (RT-PCR) validation. See 
Supplementary Methods for details.
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Erythroblast cell culture and cycloheximide treatment
Bone marrow CD34+ cells from healthy individuals were purchased from Lonza. Bone 
marrow samples were obtained and CD34+ cells isolated from two MDS patients with 
SF3B1 K700E mutation. CD34+ cells from MDS patients and from healthy controls were 
cultured as previously described.34,35 On day-11 and day-14, an aliquot of cells were 
treated with 100µg/ml cycloheximide for 4 hours and subsequently collected for RNA 
extraction. Total RNA was reverse transcribed using High capacity cDNA reverse 
transcription kit (Applied Biosystems). The expression of aberrantly spliced ABCB7 was 
determined by RT-PCR as described in the Supplementary Methods.
Generation of SF3B1-mutant K562 cells by CRISPR/Cas9 and cycloheximide treatment
See Supplementary Methods.
Pancreatic cell line Panc05.04 culture and cycloheximide treatment
See Supplementary Methods.
Results
Cryptic splicing events in HSCs of SF3B1-mutant MDS
We have analyzed RNA-Seq data obtained from the CD34+ cells from eight MDS cases 
harboring SF3B1 mutations (SF3B1-mutant, all with >15% ring sideroblasts), four MDS 
patients without splicing factor gene mutations (wildtype) and five healthy individuals 
(control)20 using rMATS, a bioinformatics pipeline designed to detect alternative (including 
cryptic) splicing events involving two isoforms from an alternatively spliced region.32 . 
These events are categorized as alternative 3′ splice site (A3SS) usage, alternative 5’ splice 
site (A5SS) usage, exon skipping, mutually exclusive exons or retained introns.
When comparing SF3B1-mutant to wildtype, we identified 126 significant splicing events 
(92 genes), of which 42 were A3SS, 6 A5SS, 8 mutually exclusive exons, 13 skipped exons 
and 57 retained introns (Table1, Table2, TableS1). When comparing SF3B1-mutant to 
controls, 213 significant splicing events (164 genes) were identified, of which 62 were 
A3SS, 10 A5SS, 12 mutually exclusive exon, 12 skipped exons and 117 retained intron 
(Table1, Table3, TableS2). Top-ranking significant genes showing at least one cryptic 
splicing event in both of these comparisons include TMEM14C, ENOSF1, SEPT6, 
DYNLL1, HINT2 and ABCC5.
We performed gene ontology analysis on the lists of significant genes showing aberrant 
splicing events identified by the rMATS pipeline using GOseq. The significant main 
ontology themes for the comparison of SF3B1-mutant to wildtype and to controls include 
‘RNA processing’ and ‘RNA splicing’ (TableS3, TableS4).
Properties of mis-regulated alternative 3´ splice sites
Compared to all alternative splicing events (regulated and unregulated) detected in the data 
by rMATS, we found a significant overrepresentation of regulated A3SS (P<1xE-08, χ2- test 
with Yates's continuity correction), but no significant overrepresentation of alternative 5’ 
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splice sites, in the comparison of SF3B1-mutant to both wildtype and controls (Table1). 
Indeed, 15/20 (75%) most significant aberrant splicing events in the comparison of SF3B1-
mutant with wildtype (Table2) and 13/20 (65%) most significant aberrant splicing events in 
the comparison of SF3B1-mutant with controls (Table3) were A3SS. These data are in 
accord with the known function of SF3B1 in the recognition of BPs and 3′ splice sites. In 
addition to A3SS, retained introns were also significantly over-represented, while cassette 
and mutually exclusive exons were under-represented.
The majority of the regulated A3SS events involved use of an A3SS upstream of the 
canonical 3´ splice site (Table1). Analysis of the sequences of upstream and downstream 
cryptic 3´ splice sites, along with their associated canonical 3´ splice sites revealed distinct 
sequence features. Both sets of canonical 3´ splice sites had extensive 18-20nt 
polypyrimidine tracts (PPTs) with enrichment of uridines at most positions (Figure1A, 
FigureS1A). In contrast the upstream cryptic sites had a shorter PPT of ~8nt with a stretch of 
4-5 A residues 13-17nt upstream. Downstream cryptic sites in the comparison of SF3B1-
mutant with wildtype also had more purine interruptions (Figure1A), but this was not 
evident in the comparison of SF3B1-mutant with control (FigureS1A). Analysis of the 
distance separating pairs of A3SS revealed a very distinct pattern for upstream cryptic 3´ 
splice sites, with a strong peak at 15nt (Figure1B, FigureS1B, blue trace; 15nt = 3.9 on log2 
scale). In contrast, downstream cryptic 3´ splice sites and A3SS unregulated by the SF3B1 
mutation showed a much broader distribution of spacing with most pairs of A3SS being 
much more widely spaced (red and green traces in Figure1B and FigureS1B). One 
interesting exception was a peak at 3nt (1.6 on log2 scale) for the unregulated A3SS which 
corresponds to the so-called NAGNAG class of A3SS36 selection of which occurs at step 2 
of splicing37 consistent with a lack of effect of SF3B1 mutation. Comparison of 3´ splice 
site strength showed that both upstream and downstream cryptic 3´ splice sites were weaker 
than their associated canonical sites in the comparison of SF3B1-mutant with wildtype 
(Figure1C), but in the comparison of SF3B1-mutant to controls only the upstream cryptic 
sites were weaker (FigureS1C). This is consistent with the adenosine interruptions of the 
PPT in the upstream cryptic sites (Figure1A, FigureS1A). We used SVM-BP finder38 to 
predict the location and strength of the top-scoring predicted BPs associated with each 
A3SS. While the predicted BP scores did not differ significantly between sets of regulated 
cryptic 3’ splice site and their associated canonical sites (Figure1D, FigureS1D), top scoring 
BPs for upstream cryptic sites were closer (median 18nt, BP-AG distance) than those for 
their associated canonical sites (median 27nt) or unregulated A3SS (median 26nt) 
(Figure1E, FigureS1E). Taken together, our data show that MDS-associated SF3B1 
mutations result in widespread use of cryptic 3´ splice sites a short distance upstream of 
canonical sites and could be consistent either with use of a common BP in association with 
upstream cryptic and canonical splice site pairs28 or, more likely, with shifted use of both 
BP and consequently 3´ splice site in the SF3B1-mutant,39,40 as shown in recent reports in 
other cancers.
Validation of cryptic 3’ splice site events
Several of the misregulated A3SS events identified by the rMATS pipeline were validated 
using RT-PCR in patient and healthy control samples. We chose TMEM14C, SEPT6, 
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HINT2, DYNLL1 and ENOSF1 for validation. These genes all showed upstream cryptic 3’ 
splice sites in the rMATS analysis with the cryptic AG site located between 11-17 
nucleotides upstream of the canonical site (FigureS2). Aberrant splicing of TMEM14C and 
DYNLL1 introduces an addition of 14 base pairs in the 5’UTR region of these genes. The 
cryptic splice site event in ENOSF1 leads to the addition of 15 base pairs (encoding five 
amino acids) to the coding sequence. Aberrant splicing of SEPT6 and HINT2 introduces an 
addition of 17 and 11 base pairs respectively, leading to a frameshift in SEPT6 and to the 
rise of a premature termination codon in the first 3 base pairs of exon 5 in HINT2. The RT-
PCR results confirmed the cryptic splicing events identified by RNA-Seq in these five genes 
in MDS patient samples with SF3B1 mutation (Figure2A, Figure2B).
Cryptic splicing of ABCB7 in HSCs of SF3B1-mutant MDS
We previously reported marked downregulation of the iron transporter ABCB7 in MDS 
patients with ring sideroblasts.11 In this study, we identified a significant A3SS event 
(FDR=0.006, inclusion level difference= -0.184) in the ABCB7 gene in the comparison of 
SF3B1-mutant to controls. Aberrant splicing introduces an addition of 21 base pairs from 
the intronic region between exons 8 and 9 causing an addition of 7 amino acids to the 
protein sequence with the last 3 base pair proximal to the canonical exon 9 giving rise to a 
premature termination codon (Figure3A, Figure3B). This result was confirmed by RT-PCR 
in patient and healthy control HSC samples: the aberrant ABCB7 transcript was observed in 
all SF3B1-mutant MDS samples analyzed (n=7), but not in any of the samples from 
wildtype patients (n=4) or from healthy controls (n=5) (Figure4A). Sanger sequencing of gel 
extract bands confirmed the presence of the addition of 21 base pairs in the aberrant ABCB7 
transcript (Figure3B). These data demonstrate that aberrant splicing of ABCB7 observed is 
specific to MDS cases carrying mutation of SF3B1.
Nonsense-mediated decay targets the aberrantly spliced ABCB7 transcript in SF3B1-
mutant MDS erythroblasts, isogenic K562-SF3B1K700E and a SF3B1-mutant pancreatic cell 
line
The presence of premature termination codons can lead to degradation of mRNA transcripts 
by nonsense-mediated RNA decay (NMD).41 We thus investigated whether the aberrantly 
spliced ABCB7 transcript containing a premature termination codon that we identified in 
SF3B1-mutant MDS is affected by NMD. CD34+ cells from two SF3B1-mutant MDS 
RARS patients and from two healthy controls were cultured using a method developed to 
study the generation of erythroblasts.34,35 Cells were collected at day 11 and day 14 of 
erythroid culture and treated with cycloheximide [an inhibitor of protein biosynthesis known 
to impair NMD42], and subjected to RT-PCR for ABCB7. The RT-PCR results showed an 
increase in the product corresponding to the aberrant ABCB7 transcript in the SF3B1-
mutant patient samples treated with cycloheximide compared to untreated samples 
(Figure4B), indicating that NMD targets the aberrantly spliced ABCB7 transcript and 
underlies the downregulation of ABCB7 observed in SF3B1-mutant MDS patients.
In addition, we performed RT-PCR for ABCB7 in K562-SF3B1K700E and SF3B1WT 
isogenic cells obtained using CRISPR/Cas9 gene editing and the pancreatic cell line Panc 
05.04 which has a heterozygous SF3B1 K700E mutation and we observed the same ABCB7 
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cryptic 3’ splice site event (Figure4C, Figure4D) which introduces a stop codon as identified 
in the CD34+ cells and cultured erythroblasts of SF3B1-mutant MDS patients. Treatment of 
K562-SF3B1K700E and Panc 05.04 cells with cycloheximide resulted in an increase of the 
aberrantly spliced form of the ABCB7 transcript (Figure4C, Figure4D).
Discussion
The splicing factor SF3B1 is the most frequently mutated gene found in MDS, and is 
strongly associated with the ring sideroblasts phenotype.5,6 It is still unknown how SF3B1 
mutations lead to the formation of ring sideroblasts in MDS. Given the critical functions of 
SF3B1 on 3′ splice site recognition, the probable consequence of this spliceosome mutation 
is aberrant splicing of various downstream target genes in MDS. The MDS arise in the HSC 
population in the bone marrow and SF3B1 is a founder mutation.43,44 It is important to 
study the impact of SF3B1 mutation on the transcriptome in the cell of origin. We sought to 
identify the aberrant/cryptic mRNA splicing events associated with the SF3B1 mutation in 
the HSC of MDS patients. We performed an analysis of RNA-Seq data that we generated 
from CD34+ cells isolated from bone marrow samples of SF3B1 mutant MDS patients with 
ring sideroblasts, MDS patients with no splicing factor gene mutation, and from healthy 
individuals.20
The recent identification of A3SS usage in other malignancies with SF3B1 mutation22,28 
highlights the importance of interrogating RNA-seq data using a method that allows the 
identification of not only annotated alternative splicing events, but also of de novo cryptic 
splicing events. In this study we used de novo transcriptome reconstruction and the rMATS 
pipeline in order to identify unannotated alternative splicing events, including A3SS and 
retained introns. We have found that SF3B1 mutations are associated with various aberrant 
splicing events in the HSC of MDS patients. Interestingly, we identified significant cryptic 
3’ splice site usage affecting many genes when comparing the transcriptome of SF3B1-
mutant MDS cases with that of MDS wildtype and control cases, in accord with the known 
role of SF3B1 in the recognition of 3′ splice sites. A3SS events were significantly over-
represented in both comparisons, but no significant overrepresentation of alternative 5’ 
splice sites was observed. Indeed, the majority (65-75%) of the most significant aberrant 
splicing events in the comparison of SF3B1-mutant to both wildtype and controls were 
A3SS. Furthermore, the number of genes with A3SS was 6-7-fold higher than the number of 
genes with alternative 5’ splice sites. These data show that aberrant 3’ splice site selection is 
a frequent and important event associated with SF3B1 mutations in the HSC of MDS 
patients.
The most distinct group of misregulated events in SF3B1-mutant MDS involved use of 
cryptic 3´ splice sites located 15-20nt upstream of the canonical 3´ splice site, consistent 
with recent reports in other cancers.28,39,40 This is an unusual location as the typical 3´ 
splice site arrangement comprises a BP typically 18-40nt upstream of the 3´ splice site, with 
an optimal separation of 19-23nt45 and a minimal separation of ~12nt.37 The 15nt 
separation of A3SS could therefore be consistent with a single BP-PPT unit from which 
either of two 3´ splice sites can be used,28 similar to Drosophila SXL exon 3.46 
Alternatively, SF3B1 mutations could lead to a shift in BP selection a short distance 
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upstream leading to altered 3´ splice site selection.39,40 For the six events that we 
investigated the predicted and mapped BP locations support the second scenario in which 
altered BP selection drives the change in 3’ splice site selection in MDS (FigureS2). This 
would be consistent with the recruitment of U2 snRNP to positions 5´ of the BP in response 
to SF3B1 targeting drugs.47 Emerging data suggest that myeloid malignancies with splicing 
factor gene mutations are preferentially susceptible to additional splicing perturbations 
induced by splicing factor inhibitors48 and this may also represent a therapeutic approach in 
SF3B1 mutant MDS.
In our study, we found at least one cryptic splicing event in TMEM14C, ENOSF1, 
DYNLL1, SEPT6 and HINT2 (validated by RT-PCR) when comparing SF3B1-mutant to 
wildtype and to controls. Importantly, cryptic splicing events affecting TMEM14C, 
ENOSF1, DYNLL1 and HINT2 have been associated with SF3B1 mutation in other cancers 
such as CLL, UM and BRCA.21–23 Emerging evidence thus suggests that there are several 
common downstream target genes in SF3B1-mutant malignancies, which may have 
implications for the design of new therapies for this group of cancers.
It most probable that several target genes showing cryptic splicing contribute to the 
phenotype observed in MDS patients with the SF3B1 mutation. We note for example that 
TMEM14C plays an important role in the terminal steps of the heme synthesis pathway.49
MDS patients with RARS suffer from a refractory anemia and show erythroid hyperplasia 
and ineffective erythropoiesis as a result of increased apoptosis in the bone marrow.50 Ring 
sideroblasts are characterized by excessive iron accumulation in the mitochondria of 
erythroid progenitors.9 The close association between SF3B1 mutations and ring 
sideroblasts is consistent with a causal relationship, and makes this the first gene to be 
strongly associated with a specific feature of MDS.5 How SF3B1 mutations affect formation 
of ring sideroblasts is still unknown.
Cryptic splicing of genes involved in iron homeostasis and/or hemoglobin synthesis could 
play a role in the ineffective erythropoiesis observed in MDS patients with SF3B1 mutation 
and ring sideroblasts.51 We reported some years ago a strong relationship between an 
increasing percentage of bone marrow ring sideroblasts in MDS patients and decreasing 
expression levels of the iron transporter ABCB7.11 The ABCB7 gene is the functional 
orthologue of the yeast Atm1p gene,52 which has been shown to be required for 
mitochondrial iron homeostasis53 and is involved in the transport of a component required 
for the maturation of iron-sulfur cluster proteins from the mitochondria to the cytosol.12 
Functional studies showing that forced expression of ABCB7 can restore erythroid growth 
and survival of RARS progenitors while decreasing the expression of aberrant mitochondrial 
ferritin (a marker for aberrant iron accumulation) subsequently implicated ABCB7 in the 
phenotype of acquired sideroblastic anemia (RARS).54 In a recent study, we performed an 
integrative analysis in MDS and the strongest association found was between the presence of 
SF3B1 mutations and marked downregulation of ABCB7.55 Given the strong correlation 
between SF3B1 mutations and the presence of ring sideroblasts,5 our data suggested a three-
way association among SF3B1 mutation, ABCB7 downregulation and the occurrence of ring 
sideroblasts. Therefore the marked downregulation of ABCB7 observed in MDS patients 
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with RARS has been recognized as an important finding for several years, however the 
mechanism underlying the downregulation of this gene in MDS has remained a mystery.
In the current study, the use of a pipeline that can detect cryptic splicing events has enabled 
the identification of A3SS usage of ABCB7 in the HSC of SF3B1-mutant MDS patients. 
Importantly, this event leads to aberrant splicing of the ABCB7 mRNA transcript, resulting 
in the addition of 7 amino acids, including a premature termination codon, to the protein 
sequence in patient samples. It is recognized that the presence of premature termination 
codons can lead to degradation of the mRNA transcript by nonsense-mediated decay 
(NMD),41 and we hypothesized that this event underlies the marked downregulation of 
ABCB7 observed in the HSC of SF3B1-mutant MDS patients. This mechanism is strongly 
supported by our data on cultured SF3B1-mutant MDS erythroblasts treated with the NMD 
inhibitor cycloheximide, showing that the aberrantly spliced ABCB7 transcript is targeted by 
NMD in erythroid cells. Importantly, we next showed that the aberrantly spliced ABCB7 
transcript was present in the myeloid cell line K562 in which the SF3B1 mutation was 
introduced using CRISPR/Cas9 gene editing, and in the pancreatic cell line Panc 05.04 
(which is mutant for SF3B1). Treatment of these two cell lines with cycloheximide resulted 
in an increase of the aberrantly spliced form of the ABCB7 transcript. These data provide 
strong evidence that the SF3B1 mutation leads to aberrant ABCB7 splicing and 
downregulation via NMD in human myeloid cells and other cancer cells. Aberrant splicing 
of ABCB7 has been reported recently in an isogenic SF3B1-mutant pre-B ALL cell line in 
another study.39 We suggest that downregulation of the iron exporter ABCB7 resulting from 
aberrant splicing of the mRNA transcript leading to NMD underlies the increased 
mitochondrial iron accumulation found in MDS patients with ring sideroblasts. Our data 
provide an important link between inherited and acquired forms of sideroblastic anemia.
It is possible that the detection of aberrantly spliced target genes, in particular ABCB7, by 
RT-PCR could form the basis of a new diagnostic test for SF3B1 mutated MDS and may 
provide valuable information in cases with suspected MDS.
Our study is the first to describe the cryptic splicing events that occur in the hematopoietic 
progenitor cells of SF3B1-mutant MDS. These data illuminate the downstream target genes 
that may play a role in the development of the MDS phenotype, and further our 
understanding of the effect of SF3B1 mutations on splicing in malignancy. We demonstrate a 
mechanism linking the presence of SF3B1 mutation in MDS RARS patients and the NMD-
induced marked downregulation of the iron transporter ABCB7, and provide strong evidence 
supporting a critical role of ABCB7 in the development of the ring sideroblasts phenotype. 
ABCB7 might represent a therapeutic target in MDS with ring sideroblasts.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Properties of A3SS misregulated in SF3B1-mutant compared to wild type SF3B1 MDS 
HSCs.
(A) Sequence logos for upstream and downstream cryptic 3’ splice sites along with their 
associated canonical sites. (B) Density plot showing distance (log2) between pairs of 3’ 
splice sites. Blue line: upstream cryptic. Red line: downstream cryptic. Green line: A3SS 
unaffected by SF3B1 mutation. (C) 3’ splice site strengths (Maximum Entropy) for 
upstream and downstream control (unregulated) A3SS, upstream cryptic sites and their 
associated canonical sites, and downstream cryptic sites and their associated canonical sites. 
(D) Branch point scores. (E) Distance of highest scoring predicted BP from associated 3’ 
splice site.(* P<0.05, ** P<0.01)
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Figure 2. Validation and semi-quantification of cryptic 3′ splice site usage in five selected genes 
from the rMATS analysis in SF3B1-mutant MDS HSC samples.
(A) PCR products of the five genes (TMEM14C, ENOSF1, DYNLL1, SEPT6 and HINT2) 
were amplified from SF3B1-mutant MDS samples (Mut), wildtype MDS samples (WT) and 
healthy control samples (HC) run on an Agilent 2100 Bioanalyzer instrument using the 
DNA 1000 kit. The aberrant transcripts (indicated by the higher band) were observed in the 
SF3B1-mutant MDS samples. (B) Semi quantification of the PCR bands showed high 
cryptic to canonical isoform ratio in the SF3B1-mutant MDS samples.
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Figure 3. Cryptic 3’ splice site usage of ABCB7 in SF3B1-mutant MDS HSCs.
(A) Visualization of RNA-Seq traces for the ABCB7 gene (intron 8-exon 9 junction) in two 
healthy controls, two MDS patients with no known splicing factor mutations and two 
SF3B1-mutant MDS cases, using Integrative Genomics Viewer (IGV). A cryptic 3’ splice 
site is observed in the ABCB7 gene between exon 8 and exon 9 in the SF3B1-mutant MDS 
cases, leading to an addition of 21 base pairs to the coding sequence causing a premature 
termination codon at the 7th amino acid (indicated with *). (B) Sanger sequencing traces of 
gel extracted bands corresponding to the canonical ABCB7 transcript and to the aberrant 
ABCB7 transcript containing the additional 21 base pairs (highlighted in blue).
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Figure 4. Aberrant splicing of ABCB7 in HSC and cultured erythroblast from SF3B1-mutant 
MDS samples, in the K562-SF3B1K700E cell line and a SF3B1-mutant pancreatic cell line.
(A) RT-PCR confirmation of aberrant splicing of ABCB7 in SF3B1-mutant MDS HSC 
samples. The higher 174bp band corresponds to the aberrant ABCB7 transcript and the 
lower 153bp band corresponds to the canonical ABCB7 transcript. The aberrant ABCB7 
transcript (higher 174bp band) was observed in the SF3B1-mutant MDS samples (Mut), but 
not in samples from wildtype MDS patients (WT) or in samples from healthy controls (HC). 
(B) Aberrant splicing of ABCB7 in cultured erythroblast from SF3B1-mutant MDS patients. 
Each panel shows data from one different SF3B1-mutant MDS patient (Mut) and from one 
different healthy control (HC). RT-PCR for ABCB7 was performed on cultured erythroblasts 
at day 11 and day 14 of culture treated with and without the nonsense-mediated decay 
inhibitor cycloheximide (CHX). The higher 174bp band corresponds to the aberrant ABCB7 
transcript and the lower 153bp band corresponds to the canonical ABCB7 transcript. The 
RT-PCR results showed an increase in the product corresponding to the aberrant ABCB7 
transcript (higher 174bp band) in the SF3B1-mutant patient samples treated with 
cycloheximide compared to untreated samples. No aberrant ABCB7 splicing was seen in the 
samples from healthy controls. (C) Aberrant splicing of ABCB7 in K562-SF3B1K700E. RT-
PCR for ABCB7 was performed on cultured K562-SF3B1K700E and K562-SF3B1WT cells 
treated with and without the nonsense-mediated decay inhibitor cycloheximide (CHX). The 
higher 174bp band corresponds to the aberrant ABCB7 transcript and the lower 153bp band 
corresponds to the canonical ABCB7 transcript. The RT-PCR results showed an increase in 
the product corresponding to the aberrant ABCB7 transcript (higher 174bp band) in the 
K562-SF3B1K700E cells treated with cycloheximide compared to the untreated cells. No 
aberrant ABCB7 splicing was seen in the K562-SF3B1WT cells untreated or treated with 
cycloheximide. (D) Aberrant splicing of ABCB7 in Panc 05.04 cells with SF3B1 mutation 
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(K700E). RT-PCR for ABCB7 was performed on cultured Panc 05.04 cells treated with and 
without the nonsense-mediated decay inhibitor cycloheximide (CHX). The higher 174bp 
band corresponds to the aberrant ABCB7 transcript and the lower 153bp band corresponds 
to the canonical ABCB7 transcript. The RT-PCR results showed an increase in the product 
corresponding to the aberrant ABCB7 transcript (higher 174bp band) in the Panc 05.04 cells 
treated with cycloheximide compared to the untreated cells.
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